Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 13/20 | 0.60 |
| ▸ | DRD2 | P14416 | 11/20 | 0.60 |
| ▸ | RAD52 | P43351 | 1/20 | 0.50 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15248910 | 0.95 | DRD4 (0.57) | DRD4DRD2CACNA1H | |
| SCHEMBL8135888 | 0.88 | DRD4 (0.55) | DRD4DRD2CACNA1HKDM4E | |
| SCHEMBL12156373 | 0.86 | DRD4 (0.56) | DRD4DRD2CACNA1HKDM4E | |
| SCHEMBL10721796 | 0.86 | DRD4 (0.65) | DRD4DRD2CACNA1H | |
| SCHEMBL25590714 | 0.84 | LMNA (0.66) | DRD4DRD2KDM4E | |
| SCHEMBL21941875 | 0.82 | DRD4 (0.56) | DRD4DRD2CACNA1HKDM4E | |
| SCHEMBL4700419 | 0.81 | ALDH1A1 (0.62) | DRD4DRD2RAD52HTR3A | |
| SCHEMBL5504349 | 0.81 | DRD2 (0.55) | DRD4DRD2RAD52KDM4EHTR3A | |
| SCHEMBL17717742 | 0.81 | DRD4 (0.55) | DRD4DRD2KDM4E | |
| SCHEMBL31596990 | 0.80 | DRD2 (0.58) | DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | MERCK PATENT GMBH (DE) | 2023-09-07 | — | — | US | disclosed |
| US-20230174538-A1 | Tricyclic heterocycles | MERCK PATENT GMBH (DE) | 2023-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278958-A1 | TRICYCLIC HETEROCYCLES | YAP1, TERF2IP, TEAD1 | DRD4 4737/4885DRD2 4711/4885RAD52 516/4885 |
| US-20230174538-A1 | Tricyclic heterocycles | YAP1, TEAD1, TERF2IP | DRD4 4697/4885DRD2 4638/4885RAD52 609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.